[Treatment of chronic heart failure: is deprescribing possible?]
Kardiologiia
; 60(3): 126-136, 2020 Jan 20.
Article
en Ru
| MEDLINE
| ID: mdl-32375625
Deprescribing is a scheduled withdrawal, dose reduction, or replacement of a medicine with a safer one. Several groups of medicinal products (MPs) are used simultaneously in the treatment of chronic heart failure. This increases the risk of adverse drug reactions, particularly in elderly and senile patients. A systematic search for literature allowed evaluating possibilities of deprescribing for the following pharmaceutic groups: 1) MPs influencing the renin-angiotensin-aldosterone system; 2) beta-blockers; 3) digoxin; and 4) diuretics. Three systematic reviews and several studies were analyzed to determine the most feasible and potentially optimal regimens of deprescribing in CHF. It was established that in CHF, deprescribing has a very limited potential for use due to the documented, obvious effect of some MP groups on prediction and severity of clinical symptoms in CHF patients.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Deprescripciones
/
Insuficiencia Cardíaca
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
Idioma:
Ru
Revista:
Kardiologiia
Año:
2020
Tipo del documento:
Article
Pais de publicación:
Rusia